FutureShape Family

NCT07872904 on ClinicalTrials.gov · last registry update 2026-10-14

An unusually large phase 4: 400 participants, more than double the 75 typical for the stage. Due to report 31 May 2030. Primary outcome, as filed: Change in body fat percentage. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Signe Torekov
Sponsor type: Other
Enrollment: 400
Started: 2026-10-01
Primary completion: 2030-05-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-14	First seen in registry	Registered as NOT_YET_RECRUITING, P4

Primary outcome

Change in body fat percentage

Conditions studied

Obesity · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.